arrow
K

Kathy D. Miller

indiana university school of medicine
H指数:75
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya

三阴性乳腺癌女性的新辅助化疗:肯尼亚西部的真实世界结果

2026-08-140
OAAI
Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171

黑种人乳腺癌患者报告的紫杉烷类诱导周围神经病变对剂量减少或生活质量恶化的影响:ECOG-ACRIN EAZ171研究分析

Cancer
IF5.1
2026-05-290
OAAI
A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer

ASTX727联合talazoparib治疗三阴性或激素抵抗/HER2阴性转移性乳腺癌的Ⅰ期研究

Cancer
IF5.1
2026-04-140
OAAI
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)

早期三阴性乳腺癌中视觉和计算评估的肿瘤浸润淋巴细胞预后价值(TBCRC-030)

2025-11-010
PRE
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer☆

循环肿瘤DNA突变景观和进展后使用CDK4/6抑制剂的动态变化:PACE II期临床试验中转移性HR阳性/HER2阴性乳腺癌☆

2025-07-250
OAAI
Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score

开发一个多机构数据集以验证一种新型炎性乳腺癌诊断评分

2025-03-310
PRE
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors (vol 14, 1376551, 2024)
2025-01-310
OAAI
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors
2024-10-291
OAAI
Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05)
2024-05-020
PRE
Development of a multi-institutional, photograph-rich clinical dataset to test and validate a novel inflammatory breast cancer (IBC) scoring system
2024-05-020
PRE
The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
2024-05-020
PRE
Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2-metastatic breast cancer: Results from the PACE phase II study
2024-03-220
PRE
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
CANCER
IF5.1
2024-01-180
PRE
Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
2023-10-012
OAAI
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

TBCRC 030中三阴性乳腺癌新辅助化疗后循环肿瘤DNA与残余肿瘤负荷的关系

2023-10-0113
OAAI